Sean P. Collins, MD, PhD, presented “Rationale for Involved Site SBRT-Enhanced Intermittent Androgen Deprivation Therapy in Nodal Oligorecurrent Prostate Cancer” during the 34th International Prostate Cancer Update on February 13, 2024, in Vail, Colorado.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Collins, Sean P. “Rationale for Involved Site SBRT-Enhanced Intermittent Androgen Deprivation Therapy in Nodal Oligorecurrent Prostate Cancer.” February 2024. Accessed Sep 2024. https://grandroundsinurology.com/rationale-for-involved-site-sbrt-enhanced-intermittent-androgen-deprivation-therapy-in-nodal-oligorecurrent-prostate-cancer/
Rationale for Involved Site SBRT-Enhanced Intermittent Androgen Deprivation Therapy in Nodal Oligorecurrent Prostate Cancer – Summary
Sean P. Collins, MD, PhD, discusses stereotactic body radiation therapy (SBRT) combined with intermittent androgen deprivation therapy (ADT) in managing nodal oligorecurrent prostate cancer. He emphasizes the evolving landscape of prostate cancer treatment, particularly in patients with limited nodal metastases, where traditional systemic approaches are being re-evaluated in favor of targeted and less toxic strategies.
Dr. Collins explores the clinical evidence supporting SBRT as a precise and effective modality that targets metastatic nodes while sparing surrounding healthy tissues. He underscores that when SBRT is combined with intermittent ADT, it provides a synergistic effect that not only controls localized disease but also allows for periodic withdrawal of ADT, thereby reducing the need for life-long hormone therapy.
Ultimately, Dr. Collins advocates for a paradigm shift toward more personalized and targeted management of nodal oligorecurrent prostate cancer. His insights provide a thoughtful analysis of the potential benefits of integrating SBRT and intermittent ADT.
About The 34th Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. The 34th iteration of the meeting occurred February 11-14, 2024 in Vail, Colorado. To view more educational presentations from IPCU 34, visit our collection page.
ABOUT THE AUTHOR
Sean P. Collins, MD, PhD, is a clinical associate professor at Georgetown University Hospital in Washington, DC. He joined his twin brother Brian on the faculty of the cancer center in July of 2006 as an attending physician in radiation oncology. Dr. Collins graduated from the Medical Scientist Training Program (MSTP) at the University of Michigan in 2001. Professor Collins completed both an internship in surgery and a residency in radiation oncology at Georgetown University Hospital. His area of expertise is prostate cancer, for which he treats patients using the CyberKnife®, a technology that allows for more accurate targeting of radiation therapy. Dr. Collins is a physician-scientist, and his work focuses on developing prostate cancer treatment protocols using stereotactic body radiation therapy (SBRT) to minimize the toxicity of radiation dose escalation. To date, he has treated over 2000 prostate cancer patients with SBRT and has presented his work at major meetings and published multiple papers on his experience in peer reviewed journals.
